Top

Annals of Surgical Oncology

Published in:

01-06-2008 | Breast Oncology

Prophylactic Surgery in the Complex Decision-Making Management of BRCA Mutation Carriers

Authors: Evangelos Briasoulis, MD, Dimosthenis Ziogas, MD, Michael Fatouros, MD

Published in: Annals of Surgical Oncology | Issue 6/2008

Excerpt

To the Editor: …

Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol 2007;14:3335–44

Moller P, Evans DG, Reis MM, et al. Surveillance for familial breast cancer: differences in outcome according to BRCA mutation status. Int J Cancer 2007;121:1017–20PubMedCrossRef

Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:115–23PubMedCrossRef

Roukos DH. 2007;Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:1555–6PubMedCrossRef

Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002;9:941–3PubMed

Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rationale of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030–4PubMedCrossRef

Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with a BRCA1/2 mutations. Ann Surg Oncol 2007. doi: 10.1245/s10434-007-9612-4.

Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007;4:578–90PubMedCrossRef

Chung DC, Yoon SS, Lauwers GY, et al. Case records of the Massachusetts General Hospital. Case 22–2007. A woman with a family history of gastric and breast cancer. N Engl J Med 2007;357:283–91PubMedCrossRef

10.

Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002;9:607–9PubMed

11.

Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007;245:873–9PubMedCrossRef

12.

Ziogas D, Baltogiannis G, Fatouros M, Roukos DH. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg (in press)

13.

Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005;2:98–107PubMedCrossRef

14.

Roukos DH, Lorenz M, Karakostas K, et al. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001;84:1602–9PubMedCrossRef

15.

Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 2000;7:253–5PubMedCrossRef

16.

Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 2004;11:127–9PubMedCrossRef

17.

Roukos DH, Hottenrott C, Encke A, et al. Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 1994;3:115–25PubMedCrossRef

18.

Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004;11:727–30PubMedCrossRef

19.

Roukos DH, Hottenrott C, Lorenz M, et al. A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach. An analysis of early results and long-term survival. J Cancer Res Clin Oncol 1990;116:307–1PubMedCrossRef

20.

Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002;81:59–62PubMedCrossRef

21.

Roukos DH. 1998 Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 80:16–24PubMed

22.

Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–30PubMedCrossRef

23.

Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002;9:220–1PubMedCrossRef

24.

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20PubMedCrossRef

25.

Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007;14:2691–5PubMed

26.

Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006;24:2437–43PubMedCrossRef

27.

Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003;10:718–21PubMedCrossRef

28.

Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005;5:737–45PubMedCrossRef

29.

Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;366:2087–106PubMed

30.

Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308–12PubMedCrossRef

31.

Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer - integrating current standards and new technologies. Expert Rev Mol Diagn 2008; 8:29–39. PubMedCrossRef

32.

Liakakos T, Roukos DH. More controversy than ever – Challenges and promises towards personalized treatment of gastric cancer: Ann Surg Oncol (in press).

33.

Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (in press).

34.

Briasoulis E, Liakakos T, Dova L,et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931–9.PubMedCrossRef

Title: Prophylactic Surgery in the Complex Decision-Making Management of BRCA Mutation Carriers
Authors: Evangelos Briasoulis, MD
Dimosthenis Ziogas, MD
Michael Fatouros, MD
Publication date: 01-06-2008
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 6/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9738-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prophylactic Surgery in the Complex Decision-Making Management of BRCA Mutation Carriers

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2008

Controversy in the Treatment of Gastric Cancer

A Common Misuse of Stepwise Regression in Studies of Ratio of Metastatic Lymph Nodes for Gastric Cancer

Soluble Intercellular Adhesion Molecule-1 as a Prognostic Marker for Stage II Colorectal Cancer Patients

Esophageal Cancers with Synchronous or Antecedent Head and Neck Cancers: A More Formidable Challenge?

Modalities of Hyperthermic Intraperitoneal Chemotherapy

Short- and Long-Term Outcomes after Hepatic Resection for Hepatocellular Carcinoma with Concomitant Esophageal Varices in Patients with Cirrhosis